Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs iShares MSCI United Kingdom (FTSE) (EWU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs iShares MSCI United Kingdom (FTSE) — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while iShares MSCI United Kingdom (FTSE) trades at $48.32. The key difference: iShares MSCI United Kingdom (FTSE) is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | EWU | |
|---|---|---|
Market Cap | $29.60B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $491.22 | $48.68 |
52-Week Low | $205.48 | $40.90 |
Enterprise Value | $27.56B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
EWU, the iShares MSCI United Kingdom ETF, trades at $48.37, down 0.25% on the day, with a bullish technical outlook supported by moving averages and strong trend indicators like ADX. Recent institutional activity includes Balefire LLC acquiring shares and Bank of America reducing its stake. The ETF is influenced by FTSE 100 performance, oil price volatility, and UK political developments under new Prime Minister Andy Burnham.
The outlook for EWU is cautiously optimistic, driven by bullish technical signals and exposure to UK equities, but risks from Middle East tensions, oil price swings, and political uncertainty may curb gains. Investors should weigh the ETF's diversification benefits against macroeconomic headwinds affecting British markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About iShares MSCI United Kingdom (FTSE)
EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.
Read more on EWU →
